Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

Proteasome inhibition is an effective treatment strategy for multiple myeloma. With improving survival, attention is increasingly focusing on ease of administration and toxicity profile. Ixazomib is an investigational, orally bioavailable 20S proteasome inhibitor. Sixty patients with relapsed and/or...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Kumar, Shaji K., Bensinger, William I., Zimmerman, Todd M., Reeder, Craig B., Berenson, James R., Berg, Deborah, Hui, Ai-Min, Gupta, Neeraj, Di Bacco, Alessandra, Yu, Jiang, Shou, Yaping, Niesvizky, Ruben
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2014
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4468583/
https://ncbi.nlm.nih.gov/pubmed/24904120
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-01-548941
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados